64th ASH Annual Meeting and Exposition: 906. Outcomes Research

Symposia: Outcomes Research—Myeloid Malignancies Oral and Poster Abstracts
Oral

Research, Acute Myeloid Malignancies, Biological therapies, AML, MDS, adult, Clinical Practice (Health Services and Quality), epidemiology, elderly, Clinical Research, health outcomes research, Diversity, Equity, and Inclusion (DEI) , Chronic Myeloid Malignancies, Diseases, Therapies, real-world evidence, Adverse Events, registries, Myeloid Malignancies, survivorship, Study Population, Human, Transplantation

220-222 (Ernest N. Morial Convention Center)

Moderators:

Rebecca L. Olin, MD, University of California, San Francisco and Eduardo M Rego, MD, PhD, University of São Paulo

Disclosures:

Olin: Cellectis: Other: NA; Astellas: Consultancy; Actinium: Consultancy; Abbvie: Consultancy.

Studies focusing real-world outcomes, healthcare services utilization and evaluation of risk in myeloid malignancies

2:00 PM

277

Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US

Pankit Vachhani, MD¹, Esprit Ma, MPH²^*, Tao Xu, PhD³^*, Melissa Montez, PharmD⁴^*, Sarah Worth, PharmD¹^*, Wei-Han Cheng, PhD⁵^*, Michael Werner, PhD⁵^*, Jonathan Abbas, MD⁶ and William Donnellan, MD⁶

¹O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL
²Genentech, Inc., South San Francisco, CA
³F. Hoffmann-La Roche Ltd, Basel, Switzerland
⁴Genentech, South San Francisco, CA
⁵AbbVie, Inc., North Chicago, IL
⁶Tennessee Oncology, Nashville, TN

2:15 PM

278

Does Race/Ethnicity Impact Umbilical Cord Blood Transplant Outcomes in a Contemporary Era?

Karen K. Ballen, MD¹, Tao Wang, PhD^2,3^*, Naya He, MPH²^*, Shahrukh Hashmi, MD, MPH^4,5^*, Leslie E. Lehmann, MD⁶, William A. Wood, MD, MPH⁷, Hemalatha G. Rangarajan, MD⁸ and Wael Saber, MD, MS²

¹Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA
²CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
³Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI
⁴Department of Internal Medicine, Mayo Clinic, Rochester, MN
⁵Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates
⁶Dana Farber Cancer Institute/Boston Children's Hospital, Boston, MA
⁷Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC
⁸Division of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Childrens Hospital, Columbus, OH

2:30 PM

279

Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry

Julia H. Joo¹, Yanwen Chen, PhD²^*, Aaron T. Gerds, MD, MS³, Anjali Advani, MD⁴, Sophia R. Balderman, MD⁵, Hetty E. Carraway, MD, MBA⁶, Abhay Singh, MD, MPH⁷ and Sudipto Mukherjee, MD, PhD, MPH⁶

¹Cleveland Clinic Lerner College of Medicine, Cleveland, OH
²Quantitative Health Sciences, Cleveland Clinic, Cleveland
³Department of Hematology and Medical Oncology,, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁴Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
⁵Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁶Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH
⁷Taussig cancer center, Cleveland Clinic, Cleveland clinic, Cleveland, OH

2:45 PM

280

Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?

Anna Sophia Moret¹^*, Eva Telzerow¹^*, Maria Cristina Sauerland, MSc²^*, Simon M. Krauss³^*, Maja Rothenberg-Thurley⁴^*, Friederike H. A. Mumm, MD¹^*, Jan Braess, MD⁵^*, Bernhard J. Wörmann, MD⁶^*, Utz Krug, MD⁷, Wolfgang E. Berdel, MD⁸, Wolfgang Hiddemann, MD, PhD¹, Karsten Spiekermann¹, Pia Heußner, MD⁹^*, Dennis Görlich, PhD¹⁰^* and Klaus H. Metzeler, MD³

¹Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany
²Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany
³Department of Hematology, Cell Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany
⁴Laboratory for Leukemia Diagnostics, Department of Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany
⁵Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany
⁶Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany
⁷Department of Medicine III, Hospital Leverkusen, Leverkusen, Germany
⁸Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
⁹Departement of Internal Medicine, Hospital Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany
¹⁰Institute of Biostatistics and Clinical Research, University of Muenster, Münster, Germany

3:00 PM

281

Effects of Autoimmune Disease on Non-High Risk MDS Outcomes: A Population Analysis

Rohit Singh, MD¹^*, David Alfonso Alejos Castillo, MD¹^*, Akshee Batra, MBBS²^*, Andrew D Sparks, MS³^*, Aditi Shastri, MD⁴, Kith Pradhan, PhD⁵^*, Neil Zakai⁶ and Diego Adrianzen Herrera, MD⁶

¹University of Vermont Medical Center, Burlington, VT
²University of Vermont Medical Center, Winooski, VT
³Biomedical Statistics Research Core at the University of Vermont, Burlington, VT
⁴Department of Oncology, Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY
⁵Department of Epidemiology & Population Health, Albert Einstein College of medicine, Bronx, NY
⁶Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT

3:15 PM

282

HLA-Haploidentical Vs Mismatched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis for AML and MDS: Is There a Winner?

Dipenkumar Modi, MD¹, Maya Shatta, M.D.²^*, Seongho Kim, Ph.D²^*, Abhinav Deol, MD¹, Andrew Kin, MD¹, Asif Alavi, MD¹, Lois Ayash, MD¹, Voravit Ratanatharathorn, MD¹ and Joseph P. Uberti, M.D., Ph.D.¹

¹Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI
²Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

906.O2.6 906. Outcomes Research—Myeloid Malignancies II